



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/021,509	12/07/2001	Marie-Claude Gingras	HO P02046US1	8559

26271 7590 03/11/2005
FULBRIGHT & JAWORSKI, LLP
1301 MCKINNEY
SUITE 5100
HOUSTON, TX 77010-3095

EXAMINER

BELYAVSKYI, MICHAEL A

ART UNIT	PAPER NUMBER
----------	--------------

1644

DATE MAILED: 03/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/021,509

Applicant(s)

GINGRAS ET AL.

Examiner

Michail A Belyavskyi

Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 13 December 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,3,5,7,9 and 11-16 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,3,5,7,9 and 11-16 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 08/30/04.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

Art Unit: 1644

DETAILED ACTION

1. Claims 1, 3, 5, 7, 9 and 11-16 are pending.
2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 12/13/04 has been entered.

Claims 1, 3, 5, 7, 9 and 11-16 drawn to a method of decreasing an immune response, a method of decreasing myeloid cell activation and a method of decreasing an inflammatory response each comprising the step of administering a soluble polypeptide variant of TREM-1 are under consideration in the instant application.

In view of the amendment, filed 12/13/04 the following rejections remain:

2. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Claims 1, 3, 5, 7, 9 and 11-16 stand rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention for the same reasons set forth in the previous Office Action, mailed 07/13/04.

Applicant's arguments, filed 12/13/04 have been fully considered, but have not been found convincing.

Applicant asserts that : (i) claims 1 and 7 have been amended to clarify the scope of the invention and to read on a soluble variant of TREM-1; (ii) although the specification does not teach how to make every soluble variant of TREM-1, the disclose functional equivalent and soluble variants would be attained by conventional and routinely practiced molecular biology techniques used by those in the art; (iii) Declaration under 37 CFR 1.132 by one of the inventors Dr. Gingras disclosed that the teaching of the present invention show that a soluble

Art Unit: 1644

TREM-1 inhibits cell function in a mouse model; (iv) Bouchon et al (Nature ,2001, 410 1103-1107) reference utilized the teaching of the present invention, thus showing the enablement of the present invention.

Contrary to Applicant's assertion, as was stated in the previous Office Action, the specification only discloses: (i) the levels of TREM-1 expression in various tissues and cell types (see Examples 4 and 5 in particular); (ii) the levels of TREM-1 splice variant, in samples collected from normal individuals and individual suffering from an autoimmune disease (see example 10 in particular); (iii) *in vitro* data indicating that TREM-1 splice variant, a polypeptide comprising SEQ ID NO:2 can down regulate LPS-induced cytokine production (see example 11 in particular); (iv) a competitive inhibitor for the ligand of TREM-1, wherein said competitive inhibitor is a polypeptide comprising SEQ ID NO:2 (see page 14 in particular). The specification does not adequately teach how effectively decrease *any* immune response or decrease myeloid cell activation or decrease an inflammatory response by administering an effective amount of *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region to decrease myeloid cell activation , or *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region that is an competitive inhibitor of the ligand to TREM-1 or a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or a soluble variant of the polypeptide sequence comprising SEQ ID NO.28. Moreover, no animals models were used to study the effectively to decrease an immune response or to decrease myeloid cell activation or to decrease an inflammatory response by administering an effective amount of by administering an effective amount of *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region to decrease myeloid cell activation , or *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region_ that is an competitive inhibitor of the ligand to TREM-1 or a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or a soluble variant of the polypeptide sequence comprising SEQ ID NO.28. The specification only states that it is envisioned that administering of TREM-1 splice variant may resulting down regulation of the inflammatory response (see page 45 in particular). Similarly, the Declaration under 37 CFR 1.132 by Dr. Gingras only stated that the inventors **envisioned** modulating inflammation in septic shock by administering a competitive inhibitor of the ligand for TREM-1 (see page 1 in particular). Moreover, the Examiner does not find a support in said declaration for the asserted statement that "Declaration under 37 CFR 1.132 by Dr. Gingras disclosed that the teaching of the present invention show that a soluble TREM-1 inhibits cell function **in a mouse model**". Dr. Gingras only stated that should the prophetic examples disclosed in the instant application be performed, the obtained results might be similar to those of Bouchon et al. However, it is noted that said the prophetic experiments have not actually been performed. In addition, Bouchon et al., (Nature ,2001, 410 1103-1107) reference only teaches a very specific mTREM-1/IgG1 fusion protein, not any compound that was used in experimental endotoxic shock on murine models. However, Bouchon et al., explicitly stressed that experimental endotoxic shock reproduced human sepsis only in part as it does not involve the replication and dissemination of bacteria (see page 1105 in particular). The

Art Unit: 1644

is no teaching or suggestion in Bouchon et al. to decrease *any* immune response or decrease myeloid cell activation or decrease any inflammatory response by administering an effective amount of *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region.

Since there is no animal model studies and data in the specification to show the effectively of decreasing *any* immune response or decreasing myeloid cell activation or decreasing any inflammatory response by administering an effective amount of *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region to decrease myeloid cell activation, or *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region that is an competitive inhibitor of the ligand to TREM-1 or a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or a soluble variant of the polypeptide sequence comprising SEQ ID NO.28 it is unpredictable how to correlate *in vitro* results with *in vivo* use. Therefore, it is not clear that the skilled artisan could predict the efficacy of a method of decreasing *any* immune response or decreasing myeloid cell activation or decreasing any inflammatory response by administering an effective amount of *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region to decrease myeloid cell activation, or *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region that is an competitive inhibitor of the ligand to TREM-1 or a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or a soluble variant of the polypeptide sequence comprising SEQ ID NO.28. Thus in the absence of working examples or detailed guidance in the specification, the intended *in vivo* uses of an effective amount of *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region to decrease myeloid cell activation, or *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region that is an competitive inhibitor of the ligand to TREM-1 or a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or a soluble variant of the polypeptide sequence comprising SEQ ID NO.28 to decrease any immune response or to decrease myeloid cell activation or to decrease any inflammatory response are fraught with uncertainties.

Also an issue that applicant has not taught how to make and/or use *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region to decrease myeloid cell activation, or *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region that is an competitive inhibitor of the ligand to TREM-1 or a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or a soluble variant of the polypeptide sequence comprising SEQ ID NO.28 to effectively decrease an immune response or decrease myeloid cell activation or decrease an inflammatory response.

“Comprising” is considered open-ended claim language and includes amino acid residues outside of the specified peptide. Therefore, a peptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 28 includes an unlimited number of amino acid sequences “comprising” an unlimited number of polypeptides. The disclosure of SEQ ID NOs: 2 and 28 cannot support

Art Unit: 1644

the entire genus of peptides comprising the amino acid sequence of SEQ ID NOs:2 and 28 as part of their sequence .

Applicant is relying upon certain biological activities and the disclosure of a single species to support an entire genus. It is well known that minor structural differences among even structurally related compounds or compositions can result in substantially different biology, expression, and pharmacology of proteins. Therefore, structurally unrelated "polypeptide comprising the amino acid sequence of SEQ ID NO:2 or a soluble variant of the polypeptide sequence comprising SEQ ID NO.28 encompassed by the claimed invention other than "a polypeptide consisting the amino acid sequence of SEQ ID NOs: 2 or 28 " would be expected to have greater differences in their activities.

Thus, Applicant has not provided sufficient guidance to enable one skill in the art to use claimed method of decreasing an immune response or a method of decreasing myeloid cell activation or a method of decreasing an inflammatory response by administering an effective amount of *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region to decrease myeloid cell activation , or *any* soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region_ that is a competitive inhibitor of the ligand to TREM-1 or a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or a soluble variant of the polypeptide sequence comprising SEQ ID NO.28 in a manner reasonably correlated with the scope of the claims. The scope of the claims must bear a reasonable correlation with the scope of enablement. *In re Fisher*, 166 USPQ 18(CCPA 1970) indicates that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute.

In view of the quantity of experimentation necessary, the unpredictability of the art, the lack of sufficient guidance in the specification, the limited working examples, and the limited amount of direction provided given the breadth of the claims, it would take undue trials and errors to practice the claimed invention.

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 37(c) of this title before the invention thereof by the applicant for patent.

Art Unit: 1644

5. Claims 1, 3, 5, 7, 9 and 11-16 stand rejected under 35 U.S.C. 102(e) as being anticipated by US Patent 6,420,526 or US Patent 6,504,010 forth in the previous Office Action, mailed 07/13/04.

Applicant's arguments, filed 05/27/04 have been fully considered, but have not been found convincing.

Applicant asserts that : (i) SEQ ID NO:2 is an entirely different chemical compound with unique features not previously recognized or anticipated. For example, the transmembrane portion of the full length TREM-1 protein in '526 and in '010 is absent in the TREM-1 of SEQ ID NO:2.

Contrary to Applicant's assertion, it is noted that sequence alignment, shown that polypeptide comprising SEQ ID NO:2 or comprising SEQ ID 28 of the instant application is 100 % identical to SEQ ID NO: 478 of US Patent '526 or 100 % identical to SEQ ID NO: 1825 of US Patent '010. It is noted that the term "comprises" is open-ended term. It means that a peptide may include additional unrecited amino acids on either or both of the N- or C- termini of given sequence and thus can read on the recited polypeptide. Moreover, US Patent '526 teaches that polypeptides of the invention comprises the extracellular domain alone or fused to the intracellular domain i.e. lacking the transmembrane domain, i.e. soluble polypeptide (see column 145, lines 1-10 in particular). Similarly, US Patent ' 010 teaches that in certain embodiments the peptides of the invention may include peptides in which an N-terminal leader sequence and/or transmembrane domain have been deleted (see column 45, lines 55-65 in particular). Also, applicant relies upon an asserted and claimed mechanism of action but does not provide objective evidence that the prior art teaching of administering of polypeptide that is identical to the claimed polypeptide comprising SEQ ID NO:2 to achieve the same therapeutic effect differs from the claimed methods.

As was stated in the previous Office Action, it is the Examiner position that US Patent '526 teaches a method of treating an immune responses and a method of modulation, i.e. decreasing an inflammatory response in a subject suffering from disease comprising administering a polypeptide of SEQ ID NO: 478 in a pharmaceutical carrier (see entire document , abstract, columns 4, 8 ,77 in particular). US Patent '526 teaches that disease are infectious disease, GVHD and septic shock (see column 77 and 132 in particular). Although the reference is silent about decreasing the activity of DAP12/TREM1 complex after administering of SEQ ID NO: 478, or that SEQ ID NO: 478 is a competitive inhibitor of the ligand to TREM-1 these functional limitations would be inherent properties of said polypeptide because it is 100 % identical with the claimed polypeptide comprising SEQ ID NO:2. Since the office does not have a laboratory to test the reference polypeptide, it is applicant's burden to show that the reference polypeptide does not decrease the activity of DAP12/TREM1 complex or not a competitive inhibitor of the ligand to TREM-1 as recited in the claims. See *In re Best*, 195 USPQ 430, 433 (CCPA 1977); *In re Marosi*, 218 USPQ 289, 292-293 (Fed. Cir. 1983); *In re Fitzgerald et al.*, 205 USPQ 594 (CCPA 1980).

Art Unit: 1644

Claims 7, 9 and 11-16 are included because the claimed functional limitation would be inherent properties of the a method of modulation an immune response and a method of modulation an inflammatory response in a subject suffering from disease comprising administering a polypeptide of SEQ ID NO: 478 taught by US Patent '526 because the referenced polypeptide of SEQ ID : 478 used in the referenced methods is 100 % identical with the claimed polypeptide comprising SEQ ID NO:2 used in the claimed methods. It is clear that US Patent '526 and the current application administered the same compound to achieved the same results in the same patients thus the reference polypeptide would inherently performed the intended use. If the prior art structure is capable of performing the intended use, then it meets the claim. When a claim recites using an old composition or structure (e.g. polypeptide of SEQ ID NO: 478) and the use is directed to a result or property of that composition or structure then the claim is anticipated. In addition, under the principles of inherency, if a prior art method, in its normal and usual operation, would necessarily perform the method claimed, then the method claimed will be considered to be anticipated by the prior art. When the prior art method is the same as a method described in the specification, it can be assumed the method will inherently perform the claimed process. See MPEP 2112.02. Also, see Bristol-Myers Squibb Co. v. Ben Venue Laboratories, Inc. 58 USPQ2d 1508 (CA FC 2001); Ex parte Novitski 26 USPQ 1389 (BPAI 1993); Mehl/Biophile International Corp. V. Milgram, 52 USPQ2d 1303 (Fed. Cir. 1999); Atlas Powder Co. V. IRECO, 51 USPQ2d 1943 (Fed. Cir. 1999).

Similarly, US Patent '010 teaches a method of therapy of an immune response in a subject suffering from disease comprising administering a polypeptide of SEQ ID NO: 1825 in a pharmaceutical carrier (see entire document , abstract, column 3, 45, 46, 78 and 79 in particular). It is noted that polypeptide compising SEQ ID :2 an of the instant application is 100 % identical to SEQ ID NO: 1825 of US Patent '010 (see attached sequence alignment). Although the reference is silent about decreasing the activity of DAP12/TREM1 complex after administering of SEQ ID NO: 1825, or that SEQ ID NO: 1825 is a competitive inhibitor of the ligand to TREM-1 these functional limitations would be inherent properties of said polypeptide because it is 100 % identical with the claimed SEQ ID NO:2. Since the office does not have a laboratory to test the reference polypeptide, it is applicant's burden to show that the reference polypeptide does not decrease the activity of DAP12/TREM1 complex or not a competitive inhibitor of the ligand to TREM-1 as recited in the claims. See *In re Best*, 195 USPQ 430, 433 (CCPA 1977); *In re Marosi*, 218 USPQ 289, 292-293 (Fed. Cir. 1983); *In re Fitzgerald et al.*, 205 USPQ 594 (CCPA 1980).

Claims 7, 9 and 11-16 are included because the claimed functional limitation would be inherent properties of the a method of modulation an immune response and a method of modulation an inflammatory response in a subject suffering from disease comprising administering a polypeptide of SEQ ID NO: 1825 taught by US Patent '010 because the referenced polypeptide of SEQ ID : 010 used in the referenced methods is 100 % identical with the claimed SEQ ID NO:2 used in the claimed methods. It is clear that US Patent '010 and the current application administered the same compound to achieved the same results in the same patients thus the reference polypeptide would inherently performed the intended use. If

Art Unit: 1644

the prior art structure is capable of performing the intended use, then it meets the claim. When a claim recites using an old composition or structure (e.g. polypeptide of SEQ ID NO: 1825) and the use is directed to a result or property of that composition or structure then the claim is anticipated. In addition, under the principles of inherency, if a prior art method, in its normal and usual operation, would necessarily perform the method claimed, then the method claimed will be considered to be anticipated by the prior art. When the prior art method is the same as a method described in the specification, it can be assumed the method will inherently perform the claimed process. See MPEP 2112.02. Also, see Bristol-Myers Squibb Co. v. Ben Venue Laboratories, Inc. 58 USPQ2d 1508 (CA FC 2001); Ex parte Novitski 26 USPQ 1389 (BPAI 1993); Mehl/Biophile International Corp. V. Milgraum, 52 USPQ2d 1303 (Fed. Cir. 1999); Atlas Powder Co. V. IRECO, 51 USPQ2d 1943 (Fed. Cir. 1999).

As pointed out previously, the mechanism of action does not have a bearing on the patentability of the invention if the invention was already known or obvious. Even though applicant has proposed or claimed the mechanism by which a particular compound decrease myeloid cell activation it does not appear to distinguish the prior art teaching the same or nearly the same methods to achieve the same endresult. Mere recognition of latent properties in the prior art does not render nonobvious an otherwise known invention. In re Wiseman, 201 USPQ 658 (CCPA 1979). Granting a patent on the discovery of an unknown but inherent function would remove from the public that which is in the public domain by virtue of its inclusion in, or obviousness from, the prior art. In re Baxter Travenol Labs, 21 USPQ2d 1281 (Fed. Cir. 1991). See M.P.E.P. 2145.

The reference teaching anticipates the claimed invention.

The following new grounds of rejection is necessitated by the amendment, filed on 12/13/04.

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 1, 3, 5, 7, 9 and 11-16 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. **This is a New Matter rejection.**

Art Unit: 1644

“soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region” claimed in claims 1 and 7; and “soluble variant of the polypeptide sequence comprising SEQ ID NO:28”, claimed in claim 14 represent a departure from the specification and the claims as originally filed. The passages pointed by the applicant do not provide a clear support for “soluble polypeptide variant of TREM-1 in which the variant lacks a functional transmembrane region” claimed in claims 1 and 7; “soluble variant of the polypeptide sequence comprising SEQ ID NO:28”, claimed in claim 14. The specification and the claims as originally filed only support “variant of TREM-1”.


8. No claim is allowed

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskiy whose telephone number is 571/ 272-0840. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571/ 272-0841.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michail Belyavskiy, Ph.D.
Patent Examiner
Technology Center 1600
February 22, 2005


CHRISTINA CHAN
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600